once-weekly semaglutide in adults with overweight or obesity pubmed Two-year effects of obesity: the STEP 5 trial pubmed semaglutide Two-year effects of

Conventional therapies targeting classical risk factors, such as hypertension, diabetes mellitus, and dyslipidemia, confer partial protective effects but do not completely halt DKD progression or sufficiently mitigate its associated cardiovascular risk [6]

Nutritional deficiencies: Nutrient deficiencies (such as iodine, zinc, vitamin D, or iron deficiency) may trigger hypothyroidism or autoimmunity

In early 2025, Viking Therapeutics announced it was entering phase 2 clinical trials for its oral GLP-1 agonist and glucose-dependent insulinotropic polypeptide receptors, Viking VK2735

Ro is committed to making healthcare easy and effective for patients and this new tool is a testament to that mission.

Contact us at 1-647-576-2076 to learn more about accessing Retatrutide and other treatments through our prescription referral service